Journal article
Geographical clustering of anal cancer incidence in Australia
IM Poynten, AN Stein, EL Conway, G Prestage, DG Regan, F Jin, J Hocking, AE Grulich
Sexual Health | CSIRO PUBLISHING | Published : 2012
DOI: 10.1071/SH12039
Abstract
Introduction: Homosexual men are at an increased risk of anal cancer. We aimed to establish the burden of anal squamous cell carcinoma (SCC) in those parts of Australia where homosexual men are most likely to live. Methods: Data on the proportion of homosexual male residents were obtained from published estimates. Men were categorised into three postcode groups by prevalence of men reporting homosexual identity. Male population data in age groups were extracted for each postcode group and analyses of cancer incidence were performed by postcode group. The analyses were restricted to 2000-2005. Results: Eight postcodes had populations where more than 10% of males reported homosexual identity (..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by NHMRC
Awarded by Australian Research Council
Awarded by CSL Limited is a partner organisation
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
IMP (#1016307) and FJ (#571402) are supported by Postdoctoral Training Fellowships from the National Health and Medical Research Council (NHMRC). AEG was supported by a NHMRC Principal Research Fellowship (#568819). The project was supported by NHMRC program grant (#568971). The Kirby Institute (formerly the National Centre in HIV Epidemiology and Clinical Research) is affiliated with the Faculty of Medicine, University of New South Wales and is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government.IMP, FJ and GP have no conflicts of interest. ELC and AS are employed by CSL Limited and own stock in CSL Limited. DGR is the recipient of an Australian Research Council Linkage Project grant (LP0883831), of which CSL Limited is a partner organisation. DGR has received honoraria from CSL Limited. JH has received honoraria from CSL Biotherapies and is a researcher on the Australian Research Council Linkage Project grant (LP0883831), of which CSL Limited is a partner organisation. AEG has received consulting fees and conference sponsorship from Merck, the manufacturer of the Gardasil quadrivalent HPV vaccine; and research funding, consulting fees and conference sponsorship from CSL Biotherapies, the Australian distributor of the Gardasil vaccine.